Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ATOS

Atossa Therapeutics Inc

Dec 11 • 09:34AM ET

1.30

Dollar change +0.04
Percentage change 2.90	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA SRPT BNTX CYTK AXSM NVAX KPTI ADAP RGLS

| Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.21	Insider Own	0.04%	Shs Outstand	125.80M	Perf Week	10.81%
Market Cap	163.10M	Forward P/E	-	EPS next Y	-0.25	Insider Trans	0.00%	Shs Float	125.75M	Perf Month	-19.97%
Income	-26.91M	PEG	-	EPS next Q	-0.06	Inst Own	21.86%	Short Float	9.23%	Perf Quarter	-13.57%
Sales	0.00M	P/S	-	EPS this Y	11.46%	Inst Trans	4.40%	Short Ratio	18.58	Perf Half Y	1.29%
Book/sh	0.59	P/B	2.20	EPS next Y	-17.65%	ROA	-29.71%	Short Interest	11.60M	Perf Year	77.31%
Cash/sh	0.60	P/C	2.18	EPS next 5Y	-	ROE	-31.30%	52W Range	0.70 - 2.31	Perf YTD	47.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.61%	ROI	-36.52%	52W High	-43.87%	Beta	1.21
Dividend TTM	-	Quick Ratio	13.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	85.21%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	13.30	EPS Y/Y TTM	9.11%	Oper. Margin	-	RSI (14)	49.58	Volatility	5.51% 6.18%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-16.16%	Payout	-	Rel Volume	2.96	Prev Close	1.26
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	624.61K	Price	1.30
SMA20	2.75%	SMA50	-5.53%	SMA200	-7.02%	Trades		Volume	110,469	Change	2.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-18	Initiated	Maxim Group	Buy	$2

Today 08:15AM	Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (GlobeNewswire)
Dec-10-24 09:05AM	Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 08:15AM	Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-21-24 08:30AM	Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-20-24 08:30AM	Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.25%
08:30AM	Loading…
Nov-12-24 08:30AM	Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.41%
Nov-05-24 08:30AM	Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development (GlobeNewswire)
Nov-04-24 06:30AM	Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (GlobeNewswire)
Oct-31-24 08:15AM	Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer (GlobeNewswire)
Oct-28-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
Oct-21-24 08:30AM	Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer (GlobeNewswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire)
Oct-14-24 05:08PM	Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-01-24 08:30AM	Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum (GlobeNewswire)
Sep-19-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:30AM	Loading…
Sep-10-24 08:30AM	Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer (GlobeNewswire) +7.35%
Sep-03-24 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-30-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice (Zacks)
Aug-28-24 08:30AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Aug-21-24 11:30AM	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer (GlobeNewswire)
Aug-20-24 08:30AM	Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations (GlobeNewswire)
Aug-12-24 08:30AM	Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.98%
Jul-22-24 08:30AM	Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire) +10.45%
Jul-11-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks) +6.67%
07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace)
Jul-03-24 09:45AM	3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 (InvestorPlace)
Jul-02-24 04:15PM	Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer (GlobeNewswire)
Jun-28-24 08:30AM	Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Jun-17-24 08:30AM	Atossa Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
10:50AM	Loading…
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-06-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 08:30AM	Atossa to Present at the Sidoti Small-Cap Investor Conference (GlobeNewswire)
May-28-24 08:30AM	Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model (GlobeNewswire)
May-20-24 12:00PM	Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy? (Zacks)
06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-15-24 08:30AM	Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
May-13-24 02:52PM	ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:50AM	Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines (GlobeNewswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
08:30AM	Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen (GlobeNewswire)
Apr-15-24 08:30AM	Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Apr-11-24 10:10AM	Atossa (ATOS) Reports Positive Results From EVANGELINE Study (Zacks)
08:30AM	Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference (GlobeNewswire)
Apr-09-24 11:59AM	Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen (GlobeNewswire) +5.14%
Apr-01-24 10:53PM	ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.11% -8.00%
04:00PM	Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient (GlobeNewswire) +20.16%
Mar-18-24 08:30AM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire)
Mar-12-24 08:30AM	Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors (GlobeNewswire) +9.17%
Mar-06-24 08:30AM	Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +12.75%
Feb-22-24 08:30AM	Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study (GlobeNewswire)
Feb-07-24 08:30AM	Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial (GlobeNewswire) +5.84%
Jan-09-24 08:30AM	Atossa Therapeutics Issues Letter to Shareholders (GlobeNewswire)
Dec-18-23 09:00AM	Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus (PR Newswire)
Dec-08-23 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-04-23 08:30AM	Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director (GlobeNewswire)
Nov-20-23 08:30AM	Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire) +8.82%
Nov-13-23 09:00AM	Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-23 09:00AM	Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors (GlobeNewswire) -6.49%
Oct-30-23 01:00PM	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group (PR Newswire)
Oct-11-23 08:30AM	Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later (PR Newswire)
Sep-18-23 09:25AM	Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment (ACCESSWIRE)
08:30AM	Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Aug-23-23 08:00AM	Atossa Therapeutics backing Endoxifen in the fight against breast cancer (News Direct)
Aug-14-23 08:30AM	Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.29%
Aug-08-23 09:00AM	Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023 (GlobeNewswire)
Jul-20-23 09:15AM	Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada (GlobeNewswire) +6.54%
Jul-13-23 04:15PM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire) -10.37%
Jul-12-23 09:00AM	50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis (ACCESSWIRE) +6.30%
Jul-10-23 09:15AM	Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
Jul-06-23 09:28PM	3 Penny Stocks to Make Your Get Rich Dreams Come True (InvestorPlace)
09:15AM	Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer (GlobeNewswire)
Jun-28-23 01:03PM	Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial (News Direct) +22.51%
09:15AM	Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial (GlobeNewswire)
Jun-27-23 09:15AM	Atossa Therapeutics Announces $10M Stock Repurchase Program (GlobeNewswire) +8.50%
Jun-22-23 04:15PM	Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023 (GlobeNewswire)
Jun-21-23 01:48PM	Atossa Therapeutics announces further patent protection for Endoxifen (News Direct)
10:13AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Jun-14-23 09:15AM	Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC (GlobeNewswire)
Jun-12-23 09:15AM	Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire)
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
May-23-23 07:00AM	Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator (GlobeNewswire) +15.02%
May-15-23 09:10AM	Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-23 09:00AM	Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices (PR Newswire)
May-09-23 09:15AM	Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-27-23 09:15AM	Atossa Therapeutics to Participate in Tribe Publics Webinar Event Redefining Breast Cancer Prevention and Treatment (GlobeNewswire)
Mar-30-23 11:00AM	We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate (Simply Wall St.)
Mar-22-23 04:05PM	Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.30% -5.14%
Mar-21-23 01:19PM	Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial (PR Newswire)
Mar-15-23 09:25AM	Atossa to Present at the Sidoti Small-Cap Virtual Conference (GlobeNewswire)
Feb-23-23 09:15AM	Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Feb-13-23 09:15AM	Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen (GlobeNewswire) +10.30%
Jan-25-23 09:15AM	Atossa Therapeutics Issues Letter to Shareholders (GlobeNewswire) +10.91%
Dec-07-22 08:00AM	Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations (GlobeNewswire) -6.85%
Nov-07-22 04:00PM	Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Finn Jonathan	Director	Apr 10 '24	Buy	1.77	25,000	44,250	25,000	Apr 11 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATOS

Atossa Therapeutics Inc

Upgrade your FINVIZ experience